Home  /  Resource Library  /  Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton’s Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton’s Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia

ASH 2019: Initial results of a phase II study investigating Tirabrutinib for treatment of Waldenstrom Macroglobulinemia.